In a radio interview today, Health Minister Andrew Little said the final Pharmac Review report will be publicised "in a matter of a few...
Myeloma
Endorsers of the ICBCC Patient Impact Statement
Last Thursday 24 February the ICBCC Policy Strategy Working Group met to discuss on the Policy Strategy to address the specific impact of the...
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG), article of the weekÂ
The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to...
CD38 directed therapy shows promise in Multiple Myeloma
Isatuximab continues to show promise as a standard of care therapy for patients with multiple myeloma refractory to lenalidomide and proteasome...
Australians have limited awareness of blood cancers, – new survey
Australians will not seek help for blood cancer symptoms: survey (thelimbic.com)